Drug Use Research & Management Program
Oregon State University, 3303 SW Bond Av CH12C, Portland, Oregon 97239-4501
Phone 503-947-5220 | **Fax** 503-494-1082

Division of Medical Assistance Programs – State of Oregon
Drug Use Review Board
Thursday, November 29, 2007 2:00-3:30 PM
Barbara Robert – Department of Human Services Building
500 Summer Street NE, Rm 137AB
Meeting Minutes

1) Call To Order

Members present: Rickland G Asai, DMD; Sherry Barrett, RPh; Patrick Bowman, RPh; Laura DeSimone, RPh; Fara Etzel, MD; George Gerding, RPh ; Dean Haxby, PharmD ; Robert M Ingle, Jr., MD, MPH; Jordan Laub, MD, MPH; Maggie Bennington-Davis, MD; Kyle Johnson, MD (via phone); **Staff** Present: Debbie Bishop (DMAP); Ann Hamer, PharmD (OSU); Rose-Ellen Hope, RPh (OSU); Kathy Ketchum (OSU); Luke Middleton (OSU); Bill Milne RPh (FH);. **Guests** present: Daniel Cohn (EDS) Felicia Fuller (Biogen Idec); Tony Molchan (Abbott); Stephanie Davis (BMS); Lori Howarth (Bayer); Jennifer Stoll; Trish McDaid O'Neill (Astra Zeneca); Jim Colyer (Astra Zeneca); David Pass (HRC); Bruce Bishop.

a) Dr. Ingle called the meeting to order 2:00pm. Attendees were introduced.
b) Membership was reviewed. There is a vacant physician seat being recruited for.
c) The Conflict of Interest Declaration as reviewed. Seven members renewed their declarations.
d) The 9/20/07 minutes were approved with no corrections. The meeting agenda was approved with the addition of 2008 meeting date selection to new business.
e) There were no public comments.

2) Old Business

a) F/u Antiepileptic PA Criteria Changes – The Board reviewed revised criteria that included suggestions from September meeting.

Action: Board recommended criteria be sent to DMAP to consider for implementation.

b) F/u Fentanyl Policy Changes

i) Fentora PA - A brief review of Fentora prescribing information was reviewed with a presentation of Fentora and Actiq utilization since Jan 2006. Dr. Bennington-Davis asked for background on Actiq utilization to insure a reduction in its use was a positive change. A prior DUR Board drug use evaluation (DUE) found the majority of patients using Actiq fell outside the labeled recommendations for use. The Board reviewed the new proposal to prior authorize Fentora using the similar approval criteria as used for Actiq currently.

Action: Board recommended criteria be sent to DMAP to consider for implementation.

ii) Fentanyl Patch Quantity Limit – The Board reviewed a brief summary of the previous transdermal fentanyl DUE and feedback from the educational intervention targeting more frequent dosing than Q72H. During the original presentation (Nov 2006 meeting) the Board recommended a quantity limit be considered upon evaluation of the educational intervention. While the absolute numbers do not allow confident conclusions, it appears the educational intervention is not well accepted. Some of this may be due to false positives because of inadequate information contained in the claims data.

Action: Board recommended criteria be sent to DMAP to consider for implementation with some modifications: 1) Exclude the 100mcg patch from the initiative 2) suggest a dose increase rather than frequency change if breakthrough pain is not limited to second and third days 3) discontinue educational intervention but continue opioid naïve education.

c) F/u Proposal to Require Valid Prescriber ID on Long-Acting Opioids – Ms. Ketchum reported that National Provider Identification numbers (NPI) will be required by Federal law in May 2008. The new Medicaid Medical Information System (scheduled implementation June 30, 2008) will include an edit to require a valid prescriber NPI is used.
d) F/u Lipitor Change Forms – Ms. Ketchum reported this intervention began the week of November 26. Forms for 242 patients and involving 178 prescribers and 119 pharmacies.
e) F/u APAP Toxicity Intervention – Ms. Ketchum reported this intervention began the week of November 26. Forms for 296 patients and involving 292 prescribers and 171 pharmacies.
f) Chronic Benzos in Elderly: Ms. Hope reported she has not been successful in getting psychiatric feedback on the proposed intervention and potential alternative therapies to offer prescribers.

Action: Board recommended OSU to rework intervention with input from psychiatry and bring back to March meeting.

g) F/u Lock-in Policy – Ms. Hope reported the lock-in change will be implemented in January 2008. She shared the client notice.

3) REPORTS
   a) DMAP Pharmacy Program Rules Update: Ms. Bishop reported the Federal Tamper Resistant Prescription mandate was delay by Congress until April 1, 2008 and that Lock-in will be implemented on January 1, 2008.
   b) ProDUR Report: Mr. Milne presented the third quarter report.
   a) Retro DUR Report: Ms. Ketchum presented the comprehensive RetroDUR report.
   b) Prescriber tools report presented by Ms. Ketchum
      i. Pocket Drug Guide: Next revision delay to Feb 1, 2008
      ii. ePocrates: Report uptake still climbing.
      iii. DUR Newsletter: APAP newsletter due out in December.
   c) Drug Utilization Trend Report - Ms. Ketchum reviewed the report.

Action: Board recommended Chantix utilization be reviewed.

   d) HRC/HSC Report – Ms. Ketchum reported HRC last met November 16 and will next meet in January. DUR Board Lipitor intervention reviewed in November. HRC recently reviewed B2-agonists and Peg-Interferon. The HRC work will be restructured to include a pharmaceutical, mental health and technology assessment committee. The HSC last met August 23 and will meet next in January. Recently developed a guideline for the non-surgical treatment of obesity and currently is supporting the work of the newly formed Health Fund Board.

4) NEW BUSINESS

a. Co-pay Evaluation: Dr. Hartung presented his analysis of the effects of the differential co-pay implemented in 2003. An overall 17% reduction in drug use was noted. Drugs used for schizophrenia and depression declined by nearly 20% immediately after the co-pay was implemented and drugs used for diabetes declined 13%. The use of generic medications increased from 52% to 59%. Ms. Ketchum presented the co-pay reduction proposal included in the Governor's Recommended Budget and scheduled for implementation in January 2008. The Board provided some feedback including: Match $0 co-pay to Wal-Mart's $4 list; consider increasing 100-day supply to non-preferred generics; $0 co-pay may increase the number of prescriptions used; There is confusion regarding the voluntary/mandatory nature of Medicaid co-pays among pharmacists and physicians.

b. 2008 Meeting Schedule - All meetings at 2-5 PM

March 6 – Wilsonville
May 22 – Salem
September 18 – Wilsonville
December 4 - Salem

Meeting adjourned at approximately 3:20pm; Co-Pay Policy Advisory Meeting held immediately after
Minutes respectfully submitted by Kathy Ketchum
Next DUR Meeting March 6 – CCTC Wilsonville